||JW Marriott Camelback Inn
||Thursday, May 31, 2012 7:30PM
||To register scroll down.
This symposium will provide a sophisticated understanding of the science of lipoprotein metabolism, and a stronger grasp on the complicated mechanisms by which HDL particle number and functionality can be bolstered to enhance the anti-atherogenic properties of HDL and reduce CVD risk. This program will also inform clinicians of diverse emergent approaches to enhance the beneficial effects of HDL.
PETER P. TOTH, MD, PhD – Chair
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
University of Illinois College of Medicine
H. BRYAN BREWER JR., MD
Director, Washington Cardiovascular Associates
Senior Research Consultant
Lipoprotein and Atherosclerosis Research
Cardiovascular Research Institute
MedStar Research Institute
Washington Hospital Center
ROBERT S. ROSENSON, MD, FACC, FACP, FAHA, FNLA
Professor of Medicine
Director, Cardiometabolic Disorders
Mount Sinai Medical Center
New York, NY
This activity is designed for cardiologists, endocrinologists, lipidologists, and other healthcare professionals involved in managing CVD risk in patients with complex dyslipidemia.
At the conclusion of this activity, participants should be able to:
- Explain current research defining the mechanisms underlying cholesteryl ester transfer protein (CETP) inhibition and its impact on HDL metabolism;
- Discuss recent evidence regarding utility of HDL as a target for CVD risk modification including the clinical implications for patient management;
- Describe the mechanisms involved in the metabolism of HDL and how they relate to atherogenesis;
- Compare the relative effectiveness of existing treatments and emergent approaches to raise HDL and reduce CVD risk.
|Registration and Dinner:
||7:30pm – 8:00pm
8:00pm – 9:15pm
HDL as a Target for Residual CVD Risk Reduction — Dr. Toth
|Complexities of HDL Particle Heterogeneity and Function — Dr. Rosenson
|Accruing Clinical Data on Novel Approaches to Increase HDL Levels — Dr. Brewer
Question and Answer Session:
9:15pm – 9:30 pm
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. If you have questions about this CME/CE activity, please contact the NLA at email@example.com. Please claim credit by June 15, 2012.
This activity is supported by an educational grant from Genentech, USA.
||CME credit provided by the National Lipid Association.
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. The National Lipid Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit(s)™. from organizations accredited by ACCME.
||CE Credit provided by Postgraduate Institute for Medicine.
||Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number – 0809-9999-12-179-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine. Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This program has been submitted to the Commission on Dietetic Registration (CDR) for 1.5 CPEUs. Contact Postgraduate Institute for Medicine www.pimed.com for details.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Event staff will be glad to assist you with any special needs (e.g. physical, dietary, etc.). Please email firstname.lastname@example.org at least 5 days prior to the program.
Jointly Sponsored By
Supported by an independent educational grant from:
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.